摘要
EMPEROR-Reduced研究是一项关于恩格列净对射血分数降低的心力衰竭(HFrEF)患者临床结局影响的临床试验。该研究共纳入3730例合并或不合并2型糖尿病的慢性心力衰竭(心衰)患者。结果发现,在标准和优化的抗心衰药物治疗基础上,恩格列净较安慰剂可显著降低HFrEF患者心血管死亡或心衰住院的复合终点发生率,且具有良好的安全性。
The EMPEROR-Reduced study is a clinical trial on the effect of empagliflozin on clinical outcomes of patients with heart failure with reduced ejection fraction(HFrEF).The EMPEROR-Reduced study included 3730 chronic heart failure patients with or without type 2 diabetes mellitus(T2DM).The result showed that based on the standardized and optimal medication of heart failure,patients in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group.
作者
黄峻
Huang Jun(The First Affliliated Hospital with Nanjing Medical Unversity,Nanjing 210029,China)
关键词
射血分数降低的心力衰竭
恩格列净
心血管死亡
心力衰竭住院
预后
Heart failure with reduced ejection fraction
Empagliflozin
Cardiovascular death
Hospitalization for heart failure
Prognosis
